082800 — Vivozon Pharmaceutical Co Income Statement
0.000.00%
- KR₩152bn
- KR₩183bn
- KR₩71bn
- 26
- 38
- 26
- 16
Annual income statement for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 44,953 | 43,592 | 57,730 | 51,564 | 71,318 |
Cost of Revenue | |||||
Gross Profit | 3,299 | 7,130 | 19,664 | 21,437 | 31,321 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 62,510 | 63,888 | 111,738 | 62,346 | 68,762 |
Operating Profit | -17,557 | -20,296 | -54,009 | -10,782 | 2,556 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22,639 | -43,822 | -75,848 | -25,342 | -2,158 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22,639 | -44,085 | -71,015 | -26,851 | -2,214 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -27,998 | -43,754 | -69,457 | -39,906 | -3,357 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -27,998 | -43,754 | -69,457 | -39,906 | -3,357 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -288 | -1,365 | -1,411 | -518 | -37.9 |
Dividends per Share |